Metformax 500

Metformin, the active ingredient in Metformax 500, is a biguanide presented as a 500 mg tablet for oral use. It lowers elevated blood glucose levels in adults with type 2 diabetes mellitus by decreasing hepatic glucose production and enhancing peripheral insulin sensitivity, making it a cornerstone therapy for managing hyperglycemia.

GNH USA supplies Metformax 500 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and other healthcare providers worldwide.

Metformax 500 (metformin) is indicated for conditions where glucose regulation is impaired.

- Type 2 diabetes mellitus: improves glycemic control and reduces HbA1c levels. - Prediabetes (impaired glucose tolerance): helps delay or prevent progression to type 2 diabetes. - Polycystic ovary syndrome: reduces insulin resistance and may improve menstrual regularity.

Metformax 500 may cause a range of adverse reactions, which are generally classified by frequency and severity.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, and diarrhea. - Metallic taste: transient metallic sensation in the mouth. - Weight loss: modest reduction in body weight. - Vitamin B12 deficiency: decreased absorption with long‑term use.

Serious or Rare Side Effects: - Lactic acidosis: a rare but life‑threatening accumulation of lactate. - Severe hypersensitivity: rash, Stevens‑Johnson syndrome, or anaphylaxis. - Hepatic dysfunction: elevated liver enzymes or hepatitis.

Before initiating Metformax 500, clinicians should consider several safety factors.

- Renal function: assess eGFR and avoid use if severely reduced. - Lactic acidosis risk: contraindicated in patients with significant hepatic or cardiac failure. - Cardiovascular disease: monitor for signs of heart failure. - Alcohol consumption: limit intake to reduce lactic acidosis risk. - Pregnancy and lactation: discuss potential risks and benefits with the prescriber. - Store at ambient temperature: keep in the original container, protect from moisture and heat.

Metformax 500 can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate acute renal failure; discontinue metformin temporarily. - Cimetidine: can increase metformin plasma concentrations, raising risk of lactic acidosis.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: may affect renal function, requiring periodic eGFR checks. - Beta‑blockers: can mask hypoglycemia symptoms. - Corticosteroids: may increase blood glucose, necessitating dose adjustments.